Based
at a custom built factory
in Inchinnan, adjacent
to Glasgow Airport and
currently employing
over 250 personnel,
Vascutek is engaged
in the research, design,
development and manufacture
of an extensive range
of sealed and unsealed
polyester and ePTFE
grafts, primarily utilizing
its unique surface and
gelatin impregnation
technology to address
the needs of vascular
and cardiovascular surgeons.
Vascutek manufactures
a wide range of sealed
knitted polyester grafts
for example, Gelseal™,
Gelsoft™, Gelsoft™
Plus and a sealed woven
polyester namely, Gelweave™.
The ePTFE range consists
of two gelatin sealed
ranges, SEALPTFE™
and Taperflo™
plus a range of unsealed
ePTFE and MAXIFLO™.
These products are internationally
recognized for their
high quality and innovative
design.
Vascutek is a
global company with
operations in more than
80 countries. This network
supports the needs of
healthcare professionals
worldwide.
At present, over 90%
of all production is
exported – the
company has won 4 Queen’s
Awards for export achievement
in 1988, 1990, 1993
and 1998, together with
a Queen’s Award
for Technological Achievement
in 1988.
Vascutek is the
market leader in Japan,
the U.K. and many European
countries. Recognition
for achieving substantial
sales in Japan was made
with the company receiving
an export award in 1992
from the Japanese External
Trade Organisation (JETRO).
Vascutek launched
Gelweave™ in 1992.
This coincided with
the company gaining
approval in Japan for
Gelsoft™. This
increased sales by 47%
versus 1991.
Our entry into the sealed
graft market in the
United States took place
in 1993 when the company
received FDA approval
for Gelseal™.
This was followed in
1995 with the introduction
of Gelsoft™, thus
allowing the company
to successfully promote
these knitted polyester
grafts. Vascutek’s
compliance with the
FDA GMP requirements
and with the Medical
Devices Directive has
allowed Vascutek
to become one of the
first medical device
manufacturers to affix
the CE mark to their
products.
1996 saw the launch
of a new fluoropolymer/polyester
composite prosthesis,
Fluoropassiv™.
The patented Fluoropassiv™
technology has a unique
fluoropolymer coating,
resulting in lowered
thrombogenicity and
enhanced healing properties.
Vascutek’s
continuing commitment
to research and development
culminates in a number
of newly developed products
that are moving into
the clinical phase and
will serve to maintain
the company’s
competitive edge in
the future.
Vascutek’s
pursuit of excellence
and its commitment to
"Quality, Innovation
and Service" remain
to the fore.
|
